Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
Résultats de la recherche
Tout
-
New York, USA, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight The graft versus host disease...
-
The study shows the practice-changing potential of using mismatched unrelated donors to expand access to all patients regardless of ancestry.
-
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft...
-
New York, USA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Graft vs. Host Disease Pipeline Space Landscape as Key 60+ Pharma Companies Working in the Space The...
-
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
-
Single pivotal Phase 3 study in acute graft-versus-host disease tosupport filing of biologics license application On track to initiate study in Q4 2021 LA JOLLA, Calif., July 12, 2021 (GLOBE...
-
Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical...
-
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
-
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
-
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...